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Summary
Background: Atrial fibrillation (AF) carries an in-
creased risk of systemic thrombo-embolism. More than 
90% of emboli in non-valvular AF originate from the 
left atrial appendage (LAA). Percutaneous closure of 
the LAA offers an alternative to long-term oral anti- 
coagulation (OAC). Amplatzer devices have been pro-
posed for this. A dedicated device (Amplatzer Cardiac 
Plug [ACP]) has been introduced to improve safety 
and efficacy compared to non-dedicated devices (NDAs, 
atrial and ventricular septal occluders) used previously 
for LAA closure. 
Objective: The present study investigated proce-
dural and clinical outcomes of LAA closure with the 
new ACP compared to NDAs.
Methods: All patients with LAA closure using an 
Amplatzer device at the Bern University Hospital, 
were entered into a prospective registry. Trans-oesoph-
ageal echocardiography (TEE) preceded LAA closure 
which was performed under local anaesthesia and flu-
oroscopic guidance only. Correct device position was 
documented by fluoroscopy and before discharge by 
trans-thoracic echocardiography (TTE). Follow-up 
TEE and clinical assessment by a neurologist were per-
formed 3–9 months later. A later follow-up was per-
formed by telephone contact.
Results: A total of 64 consecutive patients (NDA 
group n = 32, June 2002 to December 2008; ACP group 
n = 32, January 2009 to March 
2010) were included. The thrombo-
embolic CHADS
2
 score risk was 
lower in the NDA group compared 
to the ACP group (1.0 ± 1.0 versus 
2.5 ± 1.3, p = 0.44). Despite a lower 
rate of combined interventions, to-
tal fluoroscopy time and total 
amount of contrast medium were 
higher in the NDA group (28 ± 13 min 
versus 19 ± 20 min, p = 0.06, and 
424 ± 182 ml versus 226 ± 134 ml, 
p <0.01, respectively). In the NDA group, the techni - 
cal success rate was 84%, compared to 100% in the 
ACP group (p = 0.02). Device embolisation occurred in 
5 (16%) patients in the NDA group but did not occur in 
the ACP group (p = 0.02). The incidence or suspicion of 
thrombus on devices were: 2/17 (12%) in the NDA and 
6/28 (21%) in the ACP group (p = 0.10). During follow-
up (mean 7.2 ± 2.7 months, NDA long-term follow-up 
75 ± 16 months), no cerebrovascular accidents (CVA) 
occurred in either group. 
Conclusion: The ACP facilitated the transcatheter 
LAA closure procedure and improved its safety com-
pared to NDAs. It promises to enhance their favourable 
long-term results.
Key words: atrial fibrillation; stroke prevention; left 
atrial appendage; left atrial appendage closure
Introduction
Atrial fibrillation (AF) is the most common arrhythmia 
[1–3]. In Europe, the overall prevalence of AF amounts 
to 5.5% [1], increasing steeply with age (>17% in pa-
tients over 85 years). The risk of stroke due to AF in-
creases with the CHADS
2
 score [4]. The more elaborate 
CHA
2
DS
2
-VASc score features one additional point 
each for vascular disease, age between 65–74 years and 
female gender, and two points for age >75 years [5]. 
More than 90% of emboli in non-valvular AF originate 
from the left atrial appendage (LAA) [6–9]. Optimal 
prophylaxis of systemic thrombo-embolism in patients 
with AF is warranted and significantly improves prog-
nosis [10–13]. 
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clopidogrel, is less effective in stroke prevention than 
OAC [16] and therefore, (dual) anti-platelet therapy is 
not recommended as an alternative to OAC in patients 
with a CHADS
2
 score >1.
Since 1948, exclusion of the LAA has been per-
formed during cardiac surgery, particularly in mitral 
valve surgery with a high prevalence of AF [7, 17, 18]. 
Trans-catheter closure of the LAA was first introduced 
in 2001 [19]. The device used then (PLAATO) was 
abandoned in 2006. An alternative method was estab-
lished in June 2002 by use of a variety of non-dedicated 
Amplatzer occluders (NDAs, St. Jude, Plymouth, MS, 
USA) [20] and has been modified with a dedicated 
device (Amplatzer Cardiac Plug [ACP]) in 2008 [21] 
(fig. 1–3). 
In 2009, a first prospective randomised trial (PRO-
TECT AF) compared a third technique using the 
WATCHMAN device (Boston Scientific, Plymouth, 
MN, USA) with OAC and proved non-inferiority of 
trans-catheter LAA closure [22].
In the present study, NDAs (atrial septal defect 
(ASD), ventricular septal defect (VSD), patent foramen 
ovale (PFO) Amplatzer occluders) and the new ACP 
were compared with regard to procedural and follow-
up data. The initial rationale for the use of ASD, PFO 
and VSD devices was derived from their established 
user-friendliness, low thrombogenicity, high potential 
for adaptability to the widely varying anatomy of the 
LAA, and also the desire to offer an alternative to pa-
tients without protection due to lack of anticoagulation 
beyond the complex PLAATO procedure. The occa-
Oral anti-coagulation (OAC) currently using vita-
min K antagonists represents the gold standard to pre-
vent cerebrovascular accidents (CVAs) and systemic 
thrombo-embolism in patients with AF or atrial flutter 
[10, 11]. However, OAC carries a yearly risk of relevant 
bleedings, ranging from 0.9–2.7% [14]. Furthermore, 
the target international normalised ratio (INR) value 
of 2.0–3.0 proved maintained in <50% of patients [15]. 
Acetylsalicylic acid (ASA), even when combined with 
Figure 1
Left atrial appendage (LAA) occlusion with Amplatzer Occluder 
designed for septal occlusion (A) and the dedicated Amplatzer  
Cardiac Plug (B).
LA = left atrium.
Figure 2
Trans-oesophageal echocardiography of the left atrial appendage (LAA) before (A) and after (B, C) occlusion with an Amplatzer Cardiac Plug.
A
B
C
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the delivery cable. The disc in the left atrium had to 
move freely, while the anchoring disc (NDA) or lobe 
(ACP) moved only in unison with the LAA. If the im-
plant location and anchoring were not satisfactory, the 
device was recaptured and redeployed or a different 
size or shape (for NDA) was selected. An injection of 
contrast medium in several projections showing 2 discs 
or the lobe and the disc, respectively, in profile without 
overlap was performed before device release to assess 
the correct position. After releasing the device, the 
sheath was removed and haemostasis was achieved by 
manual compression performed by the patient unless 
an arterial puncture had also been performed [21]. 
The omission of intra-procedural TEE for measure-
ment or guidance offers the advantage of a more frugal, 
short, and patient-friendly procedure without need for 
general anaesthesia or deep sedation. Time is impor-
tant to avoid clots in the gear, particularly when com-
bining procedures (additional coronary or other struc-
tural interventions). Trans-thoracic echocardiography 
was performed before hospital discharge within 
24 hours of trans-catheter LAA occlusion to exclude 
 device  embolisation, pericardial effusion, or other se-
rious complications. OAC was not continued after im-
plantation. Patients were maintained on ASA 100 mg 
daily for 3–6 months and clopidogrel 75 mg daily for 
1 month, unless long-term anti-platelet therapy was 
required for another reason.
Devices
The NDAs feature two flat double discs (40–56 mm) of 
a nitinol mesh and polyester fabric with necks of vari-
able diameters and lengths. Risk for embolisation rep-
resents the main bane of NDAs. The ACP is a self-ex-
panding device, representing a modification of the Am-
platzer double-disc septal occluders and is delivered 
through a double-curved trans-septal access sheath. 
The ACP is composed of a lobe and a disc connected by 
a flexible central waist. The lobe is equipped with tiny 
hooks to enhance anchorage in the LAA. The disc 
(a remnant of the NDAs) is meant to seal the orifice of 
the LAA according to the pacifier principle (fig. 1–2). The 
ACP is available in eight lobe diameters (16–30 mm), 
and the disc exceeds that by 4–6 mm. 
Statistical analysis
Continuous variables are expressed as mean ± stan-
dard deviation. Comparisons between both groups 
were performed by a 2-sided, unpaired t test. Categori-
cal variables are reported as counts and percentages 
and compared by Chi square test. Due to small sample 
sizes with non-normal distribution, a non-parametric 
Mann-Whitney U-test was performed. Statistical sig-
nificance was assumed with a p value <0.05. All data 
were analysed by SPSS software version 15 (SPSS Inc., 
Chicago, Illinois).
sional experience of having to retract such devices from 
the LAA when inadvertently deployed too far away 
from the inter-atrial septum while attempting closure 
of wall defects, instigated the positioning of them there 
on purpose for LAA occlusion.
Methods
Study design
All patients who received an Amplatzer transcatheter 
LAA occlusion device since 2002 at the Bern University 
Hospital, were consecutively included in a prospective 
registry. Trans-oesophageal echocardiography (TEE) 
and clinical neurological assessment were performed 
3–9 months after the procedure and follow-up was up-
dated henceforth by telephone. Patients were divided 
into 2 groups according to the device: NDAs or ACP.
Procedure
TEE was performed prior to LAA closure for exclusion 
of LAA thrombi. LAA closure was performed under lo-
cal anaesthesia and fluoroscopic guidance only. Unless 
a PFO or ASD were present for passage, trans-septal 
needle puncture was performed under fluoroscopic 
guidance in anteroposterior and lateral views (fig. 4). 
Multi-plane X-ray graphy of the LAA was performed to 
assess the diameter of its neck (landing zone), to select 
the device size and – in the NDA group – the device 
type. The implant was then deployed into the LAA by 
retraction of the delivery sheath after having advanced 
the leading anchoring part of the device (left disc or 
lobe) out of it. After full deployment, sufficient anchor-
ing was assured by a well dosed and sustaining tug on 
Figure 3
Left atrial appendage (LAA) occlusion according to the pacifier principle (A, C, the 
disc sits outside the LAA like the pacifier plate outside a toddler’s mouth, B) using a 
non-dedicated Amplatzer Occluder (20 mm ASD occluder) depicted in a cadaver 
heart (D) with a 32 mm visible disc.
LA = left atrium.
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Tables 2 and 3 depict procedural results, complica-
tions, and follow-up data. Of the five device embolisa-
tions (four with ASD, one with a PFO device, all NDA 
group and all in atrial fibrillation at time of interven-
tion), four occurred intra-procedurally and one after 
leaving the laboratory (diagnosed at six months). In 
two cases, surgical removal of devices (one from the left 
atrium, one from the left ventricle) was performed 
along with surgical closure of the LAA. In 3 cases, the 
devices were removed from the descending aorta, 2 by 
vascular surgery in the groin and one by percutaneous 
removal. In the ACP group, no embolisations occurred. 
Two patients in the NDA group developed cardiac tam-
ponade resolved by pericardiocentesis. In one patient, 
an insignificant pericardial effusion was diagnosed on 
the post-procedural day but required no action.
Mean mid-term follow-up was performed 7.2 ± 
2.7 months after LAA closure. In 15 patients in the NDA 
group, follow-up TEE was not performed compared to 
Results
The baseline variables are depicted in table 1. In the 
first 32 patients receiving an Amplatzer NDA, a proto-
type of the currently available ACP without retention 
hooks was implanted in one patient. In the subsequent 
32 patients, an ACP was implanted. Age and gender 
distribution were similar in both groups.
CHADS
2
 and CHA
2-
VASc scores were lower in the 
NDA group, than in the ACP group. Prior to LAA clo-
sure, 72% of patients in the NDA group were on OAC 
compared to 50% in the ACP group despite higher 
CHADS
2
 scores in the ACP group (p = 0.07). 
The use of blood thinners is shown in figure 5. 
During follow-up, 1 patient in the NDA group resumed 
OAC compared to 2 patients in the ACP group. The in-
dication for restarting OAC after LAA occlusion was a 
thrombus on the device in 2 patients and atrial flutter 
ablation in 1 patient. 
Figure 4
Steps of ACP implantation: (1.) Septal puncture, simultaneous contrast medium injection depicts localisation and 
thickness of the inter-atrial septum. (2.) Opacification of the left atrial appendage (LAA), (3.) Deployment of lobe 
(anchoring plug). (4.) Deployment of disc. (5.) Proof of sufficient anchorage by tug test. Lobe stays put. (6.) Proof of LAA 
orifice sealing according to the pacifier principle. (7.) Disconnection from the delivery cable. (8.) Trans-septal LAA and 
patent foramen ovale (PFO) closure in one session. (9.) Pre-existing septal occluder guides later trans-septal puncture. 
LA = left atrium; RA = right atrium; LAA = left atrial appendage; PFO = patent foramen ovale.
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four patients in the ACP group. Reasons were co-mor-
bidities, embolisation of the device (5 NDA, 0 ACP) and 
patient or referring physician refusal. TEE showed in-
complete LAA closure (color Doppler jet width >5 mm) 
in 3 out of 17 patients (18%) in the NDA group, com-
pared to 1 out of 28 patients (4%) in the ACP group 
(p = 0.11) without further treatment. In 1 of 17 patients 
in the NDA group (6%), a mobile thrombus was shown. 
This patient refused re-initiation of OAC. Two and a 
half years later clot embolisation to a leg needed sur- 
gical treatment. In 1 of 17 patients (6%) in the NDA 
group and 2 of 28 (7%) in the ACP group, a non-mobile 
thrombus was shown and OAC was restarted for 
3–4 months, after which the thrombus had shrunk or 
disappeared on repeat TEE. In 4 of 28 patients of the 
ACP group (14%), a potential non-mobile thrombus at-
tached to the disc could not be ruled out. Two patients 
were  already on ASA and no further anti-thrombotics 
were deemed indicated. In one patient ASA was started 
Figure 5
Medication before and 3–6 months after left atrial appendage occlusion. 
ASA = acetylsalicylic acid; ACP = atrial cardiac plug;  
NDA = non-dedicated Amplatzer occluders.
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Table 1
Baseline variables.
Total NDA n = 32 ACP n = 32 p
 n %  n %  n %   
Male 44 69 23 72 21 66 0.22
Age at implantation 66 ± 9  63 ± 7  69 ± 10  0.05
Height (cm) 172 ± 7  175 ± 8  170 ± 9  0.02
Weight (kg) 83 ± 16   83 ± 17   83 ± 15   0.93
Atrial rhythm            
    Paroxysmal fibrillation 37 58 13 41 24 75 0.01
    Persistent/permanent fibrillation 26 41 19 59 7 22 <0.01
    Flutter 1 2  0 0  1 3  0.31
CHADS
2
 Score            
    Congestive heart failure 7 11 1 3 6 19 0.05
    Hypertension 39 61 15 47 24 75 0.02
    Age 16 25 1 3 15 47 <0.01
    Diabetes 10 16 1 3 9 28 0.01
    Stroke 20 31  7 22  13 41  0.11
Total 1.75 ± 1.4   1.0 ± 1.0   2.5 ± 1.3   0.44
Main Indication for LAA closure           
    Major bleeding or high risk of bleeding 34 53 12 38 22 69 0.01
    History of falls 4 6 1 3 3 9 0.30
    INR 2–3 not achievable 6 9 3 9 3 9  
    Physician or patient refusal of Vitamin K antagonist 20 31  16 50  4 13   <0.01
Medication before LAA closure           
    Acetylsalicylic acid 20 31 5 16 15 47 0.01
    Thienopyridine 4 6 0  0 4 13 0.04
    Dual anti-platelet therapy 3 5 0 0 3 9 0.08
    Vitamin K antagonists 39 61  23 72  16 50  0.07
INR = international normalised ratio; ACP = atrial cardiac plug; NDA = non-dedicated Amplatzer occluders; LAA = left atrial appendage.
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they are at least competitive to OAC (fig. 6). In our 
study, only one event happened in the NDA group as 
described above.
and continued indefinitely, in one patient OAC was 
 initiated and kept for 4 months, after which, however, 
no change was seen in the repeat TEE.
Neurological clinical follow-up did not reveal new 
deficits in any patient. A cerebrovascular accident did 
not occur during the follow-up period for any of the 
64 patients. No major bleedings were observed in any 
patient.
Long-term follow-up was complete in 100% of the 
NDA group (mean 75 ± 16 months, 199 patient-years). 
A total of 5 patients died during follow-up (2 cancer, 
1 heart failure, 1 pulmonary embolism, and 1 of un-
known reason one year after LAA closure). The ACP 
patients yielded 9 patient-years of follow-up, with no 
deaths.
Discussion
The study demonstrates that trans-catheter LAA clo-
sure with Amplatzer devices is fairly safe and effica-
cious with acceptable peri-interventional complication 
rates and good mid and long-term outcome. There was 
no device-related mortality. The new ACP closure de-
vice showed superior success and safety.
Abstracting from technical problems (mainly de-
vice embolisation), the off-label use of NDAs shows 
good clinical results. Based on the CHADS
2
 score [23], 
Table 2
Procedural variables.
 Total NDA ACP p
 n %  n %  n %   
Intervention           
Occluder           
    ASD 23 36 23 72 0 0
    VSD 6 9 6 19 0 0
    PFO 2 3 2 6 0 0
    Prototype 1 2 1 3 0 0
    Amplatzer Cardiac Plug 32 50  0 0  32 100   
Fluoroscopy time (min) 23 ± 18  28 ± 13  19 ± 20  0.06
Contrast medium (ml) 325 ± 189  424 ± 182  226 ± 134  <0.01
More than 1 device tried 5 8  3 9  2 6  0.64
Incidental intervention           
    Coronary angiography 47 74 29 91 18 56 <0.01
    PCI 7 11 1 3 6 19 0.05
    ASD/PFO closure 16 25 5 16 11 34 0.08
    Ablation of atrial fibrillation 9 14  3 9  6 19  0.28
Hospital stay (days) 1.6 ± 1.9   1.3 ± 0.5   1.9 ± 2.5   <0.01
Same-day procedure 5 8  0 0  5 16  0.02
ACP = atrial cardiac plug; ASD = atrial septal defect; NDA = non-dedicated Amplatzer occluders; 
PCI = percutaneous coronary intervention; PFO = patent foramen ovale; VSD = ventricular septal defect.
Figure 6
With the CHADS
2
 score of 1.0 in the NDA group, 5.5 cerebrovascular 
accidents (CVA) (100%) would have been expected during follow-up 
of 199 patient-years (long-term follow-up). With oral anticoagulation 
(OAC), a 64% reduction is anticipated (1.8 events; 36%). After LAA 
occlusion only 1 event happened (18%).
ACP = atrial cardiac plug;  
NDA = non-dedicated Amplatzer occluders.
100
90
80
70
60
50
40
30
20
10
0
100 100
40
36
38
After LAA
occluson
After LAA
occlusion
With OAC
(expected)
NDA ACP
With OAC
(expected)
With OAC
(expected)
With OAC
(expected)
0
Thromboembolic events %
original article
Cardiovascular Medicine 2013;16(4):123–130 129
Table 3
Procedural results and follow-up.
 Total NDA ACP p
 n %  n %  n %   
Procedural success 59 92 27 84 32 100 0.02
Device embolisation 5 8 5 16 0 0 0.02
Femoral arteriovenous fistula 2 3 2 6 0 0 0.15
Pericardial effusion 3 5 2 6 1 3 0.55
    Requiring pericardiocentesis 2 3 2 6 0 0 0.15
    Requiring surgery 0 0 0 0 0 0
Air embolism 2 3 1 3 1 3
Clot embolism 1 2  1 3  0 0  0.31
Mid-term follow-up           
Stroke 0/64 0 0/32 0 0/32 0
Incomplete closure of LAA on TEE 4/45 9 3/17 18 1/28 4 0.11
Pericardial effusion on TEE 0 0 0 0 0 0
Thrombus on device on TEE
    Mobile 1/45 2 1/17 6 0/28 0 0.19
    Non-mobile 3/45 7 1/17 6 2/28 7 0.87
    Possible 4/45 9 0/17 0 4/28 14 0.10
Death (device related) 0 0  0 0  0 0  0
Medication at mid-term follow up           
Acetylsalicylic acid 51/64 80 29/32 91 22/32 68 0.03
Thienopyiridine 19/64 30 13/32 41 6/32 19 0.06
Coumadin resumed later 3/64 5  1/32 3  2/32 6  0.55
ACP = atrial cardiac plug; LAA = left atrial appendage; NDA = non-dedicated Amplatzer occluders; TEE = trans-oesophageal echogram.
Both groups differed significantly with respect to 
baseline characteristics. Despite higher rates of cardio-
vascular co-morbidities of the patients in the ACP 
group, clinical outcome was similar. 
The remarkably high rate of physician or patient 
refusal of OAC as an indication for LAA closure oc-
curred spontaneously. These patients had no protec-
tion other than platelet inhibitors in some. Against 
that background, LAA occlusion with an off-label de-
vice was deemed an ethical and promising therapy.
The ACP with its hooks and its double-curved 
sheath rendered the procedure more operator-friendly, 
increased technical success, and reduced complica-
tions. In spite of that, a recently published European 
multicenter ACP registry [21] including 143 patients 
demonstrated higher failure rates and complications 
compared to our results. This may point out the fact 
that a learning curve for the technique of transcatheter 
LAA exclusion as a whole is influential. The significant 
reduction of contrast medium and shortening of fluo-
roscopy time reflects these improvements, particularly 
in light of a higher rate of additional interventions in 
the ACP group.
The slow blood flow in the fibrillating and com-
monly enlarged left atrium is thrombogenic. It comes 
as no surprise that device-associated thrombi were de-
tected in both groups. The higher rate of thrombi 
suspected in the ACP group may be explained by the 
particularly thrombogenic milieu proven by the higher 
CHADS and CHA
2
DS
2
-VASc scores of this group. Yet, 
these thrombi were mainly firmly attached to the disc 
(sort of filling in gaps when the disc was partially 
within the LAA rather than outside its orifice) and 
there were no clinical manifestations. 
New anticoagulants may be easier to administer, 
more effective, and less prone to bleeding but they still 
carry a risk of major haemorrhage. To answer the crit-
ical question of whether LAA occlusion with the ACP 
may be non-inferior or even superior to chronic antico-
agulation with warfarin or its successors dabigatran, 
rivaroxaban, or apixaban, prospective, randomised 
trials will be needed. Their results will be of pivotal 
impact for the entire concept of LAA occlusion, since 
device implantation harbours risks of serious complica-
tions. Finally a co-existence of LAA closure and OAC is 
possible as shown in some of our cases. It offers a third 
option in selected patients.
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For the short-term, radiofrequency ablation of AF 
foci offers a 77% success rate. In the long-term, how-
ever, the rate of recurrence remains high [24], antico-
agulation has generally to be continued and long-term 
data regarding rates of systemic embolism are lacking.
Study limitations
The study consisted of small sample sizes and was not 
randomised. In addition, the patients were not 
matched. Thus we cannot exclude several forms of bias 
such as operator experience and group in-homogeneity. 
Since no long-term results are available yet for the 
ACP, the current results can only be extrapolated on 
the basis of the mid-term results and the long-term re-
sults of the NDA group.
Conclusion
Trans-catheter LAA closure with ACP is safer and 
technically easier with lower peri-interventional com-
plication rates than with NDAs. Good long-term re-
sults can be expected with ACPs based on experience 
obtained with NDAs. Further studies are needed to 
demonstrate trans-catheter LAA closure to be at least 
as good as OAC for stroke prevention in patients with 
AF, with or without contraindications for OAC. Fi-
nally, the combination of OAC and device closure has 
to be looked at as neither of the two is perfect. 
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